US20230293775A1 - Bone-promoting thermoresponsive macromolecules - Google Patents
Bone-promoting thermoresponsive macromolecules Download PDFInfo
- Publication number
- US20230293775A1 US20230293775A1 US18/158,746 US202318158746A US2023293775A1 US 20230293775 A1 US20230293775 A1 US 20230293775A1 US 202318158746 A US202318158746 A US 202318158746A US 2023293775 A1 US2023293775 A1 US 2023293775A1
- Authority
- US
- United States
- Prior art keywords
- ppcn
- composition
- poly
- monomers
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002521 macromolecule Polymers 0.000 title 1
- 239000000017 hydrogel Substances 0.000 claims abstract description 50
- 239000000499 gel Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 17
- 230000008439 repair process Effects 0.000 claims abstract description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 69
- -1 poly(ethylene glycol) Polymers 0.000 claims description 45
- 239000000178 monomer Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 39
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical group OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims description 20
- 210000000988 bone and bone Anatomy 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 239000012867 bioactive agent Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- PSSYEWWHQGPWGA-UHFFFAOYSA-N [2-hydroxy-3-[2-hydroxy-3-(2-hydroxy-3-prop-2-enoyloxypropoxy)propoxy]propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(O)COCC(O)COCC(O)COC(=O)C=C PSSYEWWHQGPWGA-UHFFFAOYSA-N 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 229910021645 metal ion Inorganic materials 0.000 claims description 11
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 claims description 11
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 claims description 8
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 9
- 239000007788 liquid Substances 0.000 abstract description 8
- 238000013270 controlled release Methods 0.000 abstract description 6
- 230000011164 ossification Effects 0.000 abstract description 5
- 208000020084 Bone disease Diseases 0.000 abstract description 4
- 230000036760 body temperature Effects 0.000 abstract description 4
- 239000012876 carrier material Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 150000002500 ions Chemical class 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 description 40
- 239000000463 material Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 230000033558 biomineral tissue development Effects 0.000 description 10
- 239000002131 composite material Substances 0.000 description 8
- 229910052712 strontium Inorganic materials 0.000 description 8
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 8
- 102000004067 Osteocalcin Human genes 0.000 description 7
- 108090000573 Osteocalcin Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 102000004264 Osteopontin Human genes 0.000 description 6
- 108010081689 Osteopontin Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000006068 polycondensation reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000009616 inductively coupled plasma Methods 0.000 description 3
- 238000010603 microCT Methods 0.000 description 3
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 3
- 230000004818 osteo-differentiation Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000010526 radical polymerization reaction Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 3
- DKFUWGUUXDECDD-MPZZESAYSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(C)C)CC1=CC=C(O)C=C1 DKFUWGUUXDECDD-MPZZESAYSA-N 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010031258 SVVYGLR peptide Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003462 bioceramic Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 108010016184 phenylalanyl-histidyl-arginyl-arginyl-isoleucyl-lysyl-alanine Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229910001631 strontium chloride Inorganic materials 0.000 description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HZHXMUPSBUKRBW-FXQIFTODSA-N (4s)-4-[[2-[[(2s)-2-amino-3-carboxypropanoyl]amino]acetyl]amino]-5-[[(1s)-1-carboxyethyl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O HZHXMUPSBUKRBW-FXQIFTODSA-N 0.000 description 1
- AOLNDUQWRUPYGE-UHFFFAOYSA-N 1,4-dioxepan-5-one Chemical compound O=C1CCOCCO1 AOLNDUQWRUPYGE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VYMHBQQZUYHXSS-UHFFFAOYSA-N 2-(3h-dithiol-3-yl)pyridine Chemical compound C1=CSSC1C1=CC=CC=N1 VYMHBQQZUYHXSS-UHFFFAOYSA-N 0.000 description 1
- WMZSGGRLJFAUOU-BRYOGQHZSA-N 2-aminoacetic acid (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid (2S)-2-aminopentanedioic acid (2S)-2-amino-3-phenylpropanoic acid (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.NCC(O)=O.O[C@H]1CN[C@H](C(O)=O)C1.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CC1=CC=CC=C1 WMZSGGRLJFAUOU-BRYOGQHZSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010050777 Growth Differentiation Factors Proteins 0.000 description 1
- 102000014015 Growth Differentiation Factors Human genes 0.000 description 1
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 1
- 102100035970 Growth/differentiation factor 9 Human genes 0.000 description 1
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
- 101000893563 Homo sapiens Growth/differentiation factor 10 Proteins 0.000 description 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 1
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 1
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 1
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 1
- 101001075110 Homo sapiens Growth/differentiation factor 9 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000000026 X-ray photoelectron spectrum Methods 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 108010027234 aspartyl-glycyl-glutamyl-alanine Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108010042445 cell-binding peptide P-15 Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- HSVFKFNNMLUVEY-UHFFFAOYSA-N sulfuryl diazide Chemical class [N-]=[N+]=NS(=O)(=O)N=[N+]=[N-] HSVFKFNNMLUVEY-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release.
- PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.
- injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release.
- PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.
- compositions comprising a PPCN-based hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers and at least one bioactive agent incorporated therein and/or appended thereto.
- the bioactive agent is an additional monomer incorporated into the PPCN-based hydrogel backbone.
- the bioactive agent is ⁇ -glycerophosphate.
- the bioactive agent is a pendant group appended to a PPCN hydrogel.
- the pendant group is a small molecule.
- the pendant group is a peptide.
- the bioactive agent is a cyclic Arg-Gly-Asp (cRGD) peptide.
- the bioactive agent is an ionic crosslinking agent.
- the bioactive agent is Ca 2+ , Ba 2+ , or Sr 2+.
- compositions comprising a PPCN-based phosphate-displaying hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, poly-(N-isopropylacrylamide), and ⁇ -glycerophosphate monomers.
- the PPCN-based phosphate-displaying hydrogel comprises the structure:
- the composition is prepared by (a) polycondensation of citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and ⁇ -glycerophosphate monomers; followed by (b) free radical polymerization with poly-(N-isopropylacrylamide).
- the composition is prepared by the reactions depicted in Scheme 1.
- compositions comprising a PPCN-based peptide-displaying hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers, and a peptide covalently conjugated to carboxy groups of the citric acid monomers.
- the peptide is covalently conjugated via carbodiimide chemistry to carboxy groups of the citric acid monomers.
- the peptide is cyclic Arg-Gly-Asp (cRGD).
- the cRGD is covalently conjugated to carboxy groups of PPCN.
- the composition is prepared by reactions depicted in Scheme 2.
- compositions comprising a PPCN-based hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers, and metal ion crosslinks.
- compositions comprise metal-ion-crosslinked PPCN.
- compositions are prepared by incubating the PPCN in the presence of a salt of the metal ion.
- the metal ion is Ca 2+ , Ba 2+ , or Sr 2+.
- provided herein are methods of facilitating bone repair comprising administering a composition described herein (e.g., a PPCN-based hydrogel) to fractured or diseased bone site, and allowing the composition to gel.
- a composition described herein e.g., a PPCN-based hydrogel
- composition described herein e.g., a PPCN-based hydrogel
- a composition described herein e.g., a PPCN-based hydrogel
- FIG. 1 (a) MALDI spectrum of PPCN-cRGD major peaks include expected ionized cyclic-RGDfC at 581.7 m/z and full monomer at 1156 m/z. (b) ICP-OES of 50 mM and 100 mM Sr 2+ release from PPCN-Sr gels reveals majority of strontium is released in 1 week.
- FT-IR of PPCN-phos shows growth of peaks associated with reagent ⁇ -glycerophosphate, namely the broadening of the OH stretch at 3400 nm ⁇ 1 and growth of a new peak around 1238 nm ⁇ 1 attributed to phosphonate. Elemental analysis corroborates this data with a small reduction in carbon due to the displacement of carbon-rich PEG chains by ⁇ -glycerophosphate.
- FIG. 2 Rheological characterization of PPCN (a) as compared to PPCN-cRGD (b), PPCN-Sr (c) and PPCN-phos (d) confirms that all three osteoinductive variants maintain thermoresponsive behavior and exhibit a lower LCST transition than PPCN.
- FIG. 4 Day 3 and 10 alkaline phosphatase (ALP) activity shown for (a) hMSCs and (b) MC3T3s. No significant increase in ALP is detected for hMSCs at day 10. However, significant increase in ALP is detected for MC3T3s grown in PPCN-Sr and PPCN-phos gels. *P-value ⁇ 0.05 and **P-value ⁇ 0.01.
- FIG. 5 Day 21 characterization of hMSCs via staining for calcium deposition by Alizarin Red S, immunohistochemistry for osteopontin (OPN), and osteocalcin (OCN). Corresponding quantification is shown on the right. Mineralization is seen in all three functionalizations. From the data, osteopontin expression is highest in PPCN-Sr and osteocalcin expression is highest in PPCN-phos.
- FIG. 6 MicroCT analysis of intramuscular femoral injection of PPCN and PPCN-Sr is shown from day 0 to day 42.
- the top right panel orients the microCT images onto the mouse femur.
- Mineralization is observed in the PPCN-Sr group beginning at day 10 and increasing consistently through the 6 week period. No mineralization is observed in the non-functionalized PPCN control. Mineralized regions were quantified with Osirix by threshold intensity and reconstructed to show the 3D inlay.
- FIG. 7 PPCN-Sr demonstrates significant osteocalcin expression and cell infiltration (b) as compared to PPCN control (a). Alizarin Red S staining for mineralization also demonstrates robust mineralization in PPCN-Sr (d) as detected by red calcium deposits and compared to non-functionalized PPCN (c). Full tissue section is shown for PPCN and PPCN-Sr in (e) and (f), respectively.
- FIG. 8 Day 42 ICP analysis of 8 mouse organs shows that strontium is not present in any of the main organs upon digestion (a). Additionally, XPS analysis of sectioned muscle tissue show that strontium is cleared and no longer present at the site of injection (b). XPS analysis shows calcium, phosphate and oxygen content consistent with mineralization in the PPCN-Sr group, but no local strontium remaining at week 6.
- the term “and/or” includes any and all combinations of listed items, including any of the listed items individually.
- “A, B, and/or C” encompasses A, B, C, AB, AC, BC, and ABC, each of which is to be considered separately described by the statement “A, B, and/or C.”
- the term “comprise” and linguistic variations thereof denote the presence of recited feature(s), element(s), method step(s), etc. without the exclusion of the presence of additional feature(s), element(s), method step(s), etc.
- the term “consisting of” and linguistic variations thereof denotes the presence of recited feature(s), element(s), method step(s), etc.
- the term “substantially all,” “substantially complete” and similar terms refer to greater than 99%; and the terms “substantially none,” “substantially free of,” and similar terms refer to less than 1%.
- polymer refers to a chain of repeating structural units or “monomers”, typically of large molecular mass. Examples of polymers include homopolymers (single type of monomer subunits), copolymers (two types of monomer subunits), and heteropolymers (e.g., three or more types of monomer subunits).
- oligomer refers to a polymer of only a few monomer units (e.g., 2, 3, 4, 5, or more) up to about 50 monomer units, for example a dimer, trimer, tetramer, pentamer, hexamer . . . decamer, etc.
- linear polymer refers to a polymer in which the molecules form long chains without branches or crosslinked structures.
- branched polymer refers to a polymer comprising a polymer backbone with one or more additional monomers, or chains or monomers, extending from polymer backbone. The degree of interconnectedness of the “branches” is insufficient to render the polymer insoluble.
- pre-polymer refers to linear or branched polymers (e.g., not significantly crosslinked) that have the capacity to be crosslinked under appropriate conditions (e.g., to “cure” and/or form a thermoset or hydrogel), but have not been subjected to the appropriate conditions.
- crosslinked polymer refers to a polymer with a significant degree of interconnectedness between multiple polymer strands, the result of which is an insoluble polymer network.
- multiple polymer stands may be crosslinked to each other at points within their structures, not limited to the ends of the polymer chains.
- biocompatible refers to materials, compounds, or compositions means that do not cause or elicit significant adverse effects when administered to a subject.
- examples of possible adverse effects that limit biocompatibility include, but are not limited to, excessive inflammation, excessive or adverse immune response, and toxicity.
- hydrogel refers to a three-dimensional (3D) crosslinked network of hydrophilic polymers that swells, rather than being dissolved, in water.
- thermoresponsive refers to material that exhibit altered physical characteristics at different temperature ranges. Particularly relevant herein are “phase-transitioning thermoresponsive” materials. Phase-transitioning thermoresponsive” materials are soluble or in a liquid state at a first temperature range (e.g., below 26° C.) and insoluble or in a solid state at a second temperature range (e.g., 30-45° C.).
- first temperature range e.g., below 26° C.
- second temperature range e.g., 30-45° C.
- injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material for ions or therapeutics, and gel at body temperature to allow for controlled release.
- materials are antioxidant and can promote bone formation based on material properties, without osteogenic supplementation.
- materials comprise, for example, bone-promoting agents, such as phosphate, cRGD, and/or strontium.
- thermoresponsive hydrogels comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers.
- thermoresponsive hydrogels are PPCN-based hydrogels.
- a PPCN-based hydrogel comprises citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers and one or more additional monomer groups (e.g., ⁇ -glycerophosphate).
- a PPCN-based hydrogel comprises citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers and is conjugated to one or more bioactive agents (e.g., metal ions (e.g., Sr 2+ ), peptides (e.g., cRGD), etc.).
- bioactive agents e.g., metal ions (e.g., Sr 2+ ), peptides (e.g., cRGD), etc.
- negatively-charged carboxyl groups on the PPCN-based hydrogels conjugate positively charged metal ions (e.g., Sr 2+ , Ca 2+ , Ba 2+ , etc.).
- metal ions e.g., Sr 2+ , Ca 2+ , Ba 2+ , etc.
- coordination of metal ions by separate carboxyl groups results in crosslinks in the PPCN-based polymer.
- materials herein are not limited by the identity of the metal ion.
- metal ions are introduced as salts to the PPCN-based materials.
- carboxyl groups on the PPCN-based hydrogels are conjugated via appropriate linker chemistry to peptides or bioactive small molecules.
- suitable chemistires for linking bioactive peptides and/or small molecules to the PPCN-based hydrogels include alkyne/azide, thiol/maleimide, thiol/haloacetyl (e.g., iodoacetyl, etc.), thiol/pyridyl disulfide (e.g. pyridyldithiol, etc.), sulphonyl azides/thio acids, etc.
- a bioactive peptide that facilitate bone healing and/or repair is conjugated to a PPCN-based hydrogel.
- Suitable peptides include the P-15 peptide (Bhatnagar et al. Tissue Eng.1999; 5(1):53-65.; incorporated by reference in its entirety), an RGD containing peptide (Ruoslahti & Pierschbacher. Cell.
- GFOGER glycine-phenylalanine-hydroxyproline-glycine-glutamate-arginine
- CBM collagen-binding motif
- DGEA Asp-Gly-Glu-Ala
- SVVYGLR Ser-Val-Val-Tyr-Gly-Leu-Arg
- KRSR lysine-arginine-serine-arginine
- FHRRIKA Phe-His-Arg-Arg-Ile-Lys-Ala
- FN Fibronectin
- PPCN or a PPCN-based polymer or hydrogel comprises comprise at least 0.1% citric acid monomers (e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%).
- citric acid monomers e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%.
- polymers herein comprise less than 99% citric acid monomers (e.g., ⁇ 99%, ⁇ 98%, ⁇ 95%, ⁇ 90%, ⁇ 80%, ⁇ 70%, ⁇ 60%, ⁇ 50%, ⁇ 40%, ⁇ 30%, ⁇ 20%, ⁇ 10%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%, ⁇ 0.5%,).
- polymers comprise about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% citric acid monomers.
- PPCN or a PPCN-based polymer or hydrogel comprises comprise at least 0.1% polyethylene glycol monomers (e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%).
- polymers herein comprise less than 99% polyethylene glycol monomers (e.g., ⁇ 99%, ⁇ 98%, ⁇ 95%, ⁇ 90%, ⁇ 80%, ⁇ 70%, ⁇ 60%, ⁇ 50%, ⁇ 40%, ⁇ 30%, ⁇ 20%, ⁇ 10%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%, ⁇ 0.5%,).
- polymers comprise about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% polyethylene glycol monomers.
- PPCN or a PPCN-based polymer or hydrogel comprises at least 0.1% glycerol 1,3- diglycerolate diacrylate monomers (e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%).
- glycerol 1,3- diglycerolate diacrylate monomers e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%.
- polymers herein comprise less than 99% glycerol 1,3- diglycerolate diacrylate monomers (e.g., ⁇ 99%, ⁇ 98%, ⁇ 95%, ⁇ 90%, ⁇ 80%, ⁇ 70%, ⁇ 60%, ⁇ 50%, ⁇ 40%, ⁇ 30%, ⁇ 20%, ⁇ 10%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%, ⁇ 0.5%).
- glycerol 1,3- diglycerolate diacrylate monomers e.g., ⁇ 99%, ⁇ 98%, ⁇ 95%, ⁇ 90%, ⁇ 80%, ⁇ 70%, ⁇ 60%, ⁇ 50%, ⁇ 40%, ⁇ 30%, ⁇ 20%, ⁇ 10%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%, ⁇ 0.5%).
- polymers comprise about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% glycerol 1,3-diglycerolate diacrylate monomers.
- PPCN or a PPCN-based polymer or hydrogel comprises at least 0.1% N-isopropylacrylamide monomers (e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%).
- polymers herein comprise less than 99% N-isopropylacrylamide monomers (e.g., ⁇ 99%, ⁇ 98%, ⁇ 95%, ⁇ 90%, ⁇ 80%, ⁇ 70%, ⁇ 60%, ⁇ 50%, ⁇ 40%, ⁇ 30%, ⁇ 20%, ⁇ 10%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%, ⁇ 0.5%).
- polymers comprise about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% N-isopropylacrylamide monomers.
- materials described herein comprise composites of the PPCN-based thermoresponsive hydrogel materials described herein and one or more additional components.
- additional components comprise 1-99 wt % of the composite material (e.g., 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or ranges therebetween).
- a composite material comprises at least 1% (e.g., >>1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%) PPCN-based hydrogel.
- thermoresponsive composite material comprises less than 99% (e.g., ⁇ 99%, ⁇ 98%, ⁇ 95%, ⁇ 90%, ⁇ 80%, ⁇ 70%, ⁇ 60%, ⁇ 50%, ⁇ 40%, ⁇ 30%, ⁇ 20%, ⁇ 10%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, ⁇ 1%) PPCN-based hydrogel.
- a composite material comprises a PPCN-based hydrogel in an amount of about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or ranges therebetween.
- the aforementioned percentages may be wt % or molar %.
- thermoresponsive PPCN-based hydrogel materials and a bioceramic component include hydroxyapatite (HA; Ca 10 (PO 4 ) 6 (OH) 2 ), tricalcium phosphate beta ( ⁇ TCP; Ca 3 (PO 4 ) 2 ), and mixtures of HAP and ⁇ TCP.
- composite materials comprise a PPCN-based hydrogel and one or more additional polymeric components.
- Suitable biodegradeable polymers include, but are not limited to: collagen, elastin, hyaluronic acid and derivatives, sodium alginate and derivatives, chitosan and derivatives gelatin, starch, cellulose polymers (for example methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), casein, dextran and derivatives, polysaccharides, poly(caprolactone), fibrinogen, poly(hydroxyl acids), poly(L-lactide) poly(D,L lactide), poly(D,L-lactide-co-glycolide), poly(L-lactide-co-glycolide), copolymers of lactic acid and glycolic acid, copolymers of ⁇ -caprolactone and lactide, copolymers
- Suitable non-biogregradable polymers include silicone rubber, polyethylene, acrylic resins, polyurethane, polypropylene, and polymethylmethacrylate.
- PPCN-based materials comprising curable (e.g., thermoresponsive) hydrogels and/or and composites thereof. These materials find use in a variety of applications. For example, any application in which it is desired that a material be applied in a liquid and/or soluble form, and then is (rapidly) rendered solid and/or insoluble when exposed to desired conditions (e.g., physiological temperature). Materials described herein find use, for example, in medical and dental bone repair applications, such as, repair of craniofacial injuries, stabilizing complex fractures, promoting bone growth, bone regeneration, as a bone-void filler, adhering implants, etc. In some embodiments, materials find use in non-medical/dental applications.
- the PPCN-based materials described herein are liquid at sub-physiologic temperatures (e.g., 36° C., 35° C., 34° C., 33° C., 32° C., 31° C., 30° C., 29° C., 28° C., 27° C., 26° C., 25° C., 24° C., 23° C., 22° C., 21° C., 20° C., or lower or ranges therebetween).
- sub-physiologic temperatures e.g., 36° C., 35° C., 34° C., 33° C., 32° C., 31° C., 30° C., 29° C., 28° C., 27° C., 26° C., 25° C., 24° C., 23° C., 22° C., 21° C., 20° C., or lower or ranges therebetween.
- the PPCN-based materials described herein gel at or near physiologic temperatures (e.g., 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C., 40° C., or ranges therebetween).
- physiologic temperatures e.g., 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C., 40° C., or ranges therebetween.
- the materials herein are used for the repair, stabilization, regeneration, growth, etc. of bone or bone fractures/injuries
- the materials further comprise additional components/agents to facilitate incorporation into bone, bone growth, bone regeneration, etc.
- additional components/agents are incorporated into the materials and are subsequently encapsulated within the material upon curing.
- additional components/agents are non-covalently associated with the PPCN-based hydrogels and other components of the materials.
- additional components/agents are covalently-linked PPCN-based hydrogel.
- the materials described herein find use in the delivery of growth factors or other bioactive agents for the repair of bone defects and/or regeneration of bone.
- Suitable agents for use in embodiments herein include bone morphogenic proteins (e.g., BMP-1, BMP-2, BMP-4, BMP-6, and BMP-7); members of the transforming growth factor beta (TGF- ⁇ ) superfamily including, but not limited to, TGF- ⁇ 1, TGF- ⁇ 2, and TGF- ⁇ 3; growth differentiation factors (GDF1, GDF2, GDF3, GDFS, GDF6, GDF7, myostatin/GDF8, GDF9, GDF10, GDF11, and GDF15); vascular endothelial growth factor (VEGF); fibroblast growth factor (FGF); etc.
- TGF- ⁇ transforming growth factor beta
- growth differentiation factors GDF1, GDF2, GDF3, GDFS, GDF6, GDF7, myostatin/GDF8, GDF9, GDF10, GDF11, and GDF15
- VEGF
- the PPCN-based hydrogels herein find use as a carrier for therapeutics (e.g., osteoporotic drugs), cells (e.g., stem cells), growth factors, etc.
- therapeutics e.g., osteoporotic drugs
- cells e.g., stem cells
- growth factors e.g., growth factor, etc.
- the PPCN-based hydrogels herein provide controlled, localized delivery of bioactive agents encapsulated therein.
- provided herein are methods comprising administering a composition comprising a PPCN-based hydrogel described herein to a bone defect or fracture. In some embodiments, provided herein is the use of a PPCN-based hydrogel described herein to repair a bone defect or fracture.
- the PPCN-based hydrogels described herein are injected into a fracture site (e.g., during orthopedic surgery) to facilitate and/or accelerate healing.
- hMSCs human mesenchymal stem cells
- DMEM Dulbecco's Modified Eagle medium
- FBS penicillin-streptomycin
- hMSCs used in these studies were at passage 6 or below.
- Murine pre-osteoblast MC3T3-E1 cells ATCC were cultured in DMEM:F12. Both cell lines were cultured at 37° C. and 5% carbon dioxide (CO 2 ).
- PPCN poly (polyethylene glycol citrate-co-N-isopropylacrylamide) was prepared by polycondensation and subsequent radical polymerization.
- PPCN-cRGD gels PPCN was formed as reported. Then, cyclic RGDfC peptide (ABI Scientific) was covalently conjugated via maleimide chemistry to the available carboxy groups of citric acid within the PPCN polymer chain (Scheme 2). The intended density of cyclic RGD peptide was 10%.
- PPCN-Sr gels PPCN was dissolved in PBS (1 ⁇ ) at 100 mg/ml. 100 mM of SrCl 2 6H 2 O (Sigma) was mixed into PPCN/PBS solutions and left to crosslink overnight at 4° C. (Scheme 2).
- FIG. 1 Characterization for gels is shown in FIG. 1 .
- PPCN-cRGD conjugation was confirmed by matrix assisted laser desorption ionization (MALDI) ( FIG. 1 a ).
- MALDI matrix assisted laser desorption ionization
- the samples were prepared with an alpha-cyano-4-hydroxycinnamic acid matrix.
- PPCN-Sr was characterized by a strontium release study via inductively coupled plasma optical emission spectroscopy (Thermo iCAP 7600 ICP-OES). Gels were immersed in simulated body fluid and solution was removed over a 14 day time course and assayed for Sr 2+ concentration ( FIG. 1 b ).
- PPCN-phos was characterized by FT-IR (Bruker Tensor 37) and XPS ( FIG. 1 c ).
- Cells were encapsulated in various thermoresponsive PPCN solutions of 100 mg/mL PPCN in PBS (1 ⁇ ). Cells were added to solution via uniform mixing at a concentration of 1 ⁇ 10 5 cells/mL liquid PPCN. The cell-PPCN mixture was incubated at 37° C. for 5 min to allow gels to form. Once the gel was formed, warm media was added on top and changed every 2 days. Prior to seeding, the plate was coated with Sigma-cote to prevent cell attachment to the plate, ensuring that all cells that persist through media changes persist within the 3D gel environment. During handling, the plates were kept on a plate-warmer to ensure the gel would not be dissolved or diluted as a result of temperature fluctuations. At each time-point, the media was removed and the gel was collected and frozen in the case of ALP and DNA analysis or assayed directly in the case of LIVE/DEAD, alizarin red staining, and immunohistochemistry.
- alkaline phosphatase was measured.
- the gels were collected at day 3 and day 10 and extracellular alkaline phosphatase (ALP) activity was detected by a fluorometric kit (Biovision).
- MUP 4-Methylumelliferyl phosphate disodium salt
- the fluorescence was read on a micro-plate reader.
- the enzymatic activity was calculated based on serially diluted gel standards and normalized to total DNA content with a concurrent Quant-iT PicoGreen assay (Thermo Fisher).
- mice were anesthetized with isoflurane and placed on the heated microCT bed. Images were acquired with a preclinical microPET/CT imaging system, nanoScan scanner (Mediso-USA, Boston, Mass.). Data were acquired with “medium” magnification, 33 ⁇ m focal spot, 1 ⁇ 1 binning, with 720 projection views over a full circle, with a 300 ms exposure time. Images were acquired using 35 kVp. The projection data was reconstructed with a voxel size of 68 ⁇ m using filtered back-projection software from Mediso. The reconstructed data were visualized and segmented in Osirix Lite for Mac.
- images were quantified by creating regions of interest (ROI) with 2D region-growing using a lower threshold of 600 and an upper threshold of 10,000 Hounsfield units (HU).
- the regions of interests (ROIs) were used for quantification of mineralization by calculating the mean HU for each ROI (bone is 700 to 3,000 HU).
- Strontium distribution was assayed in several main organs namely the heart, brain, spleen, testes, muscle, lung, kidney, and liver. After euthanization, each organ was collected and stored in ⁇ 80° C. until analysis. Tissue digestion was carried out by adding 70% nitric acid and 37% hydrogen peroxide to each sample. Samples were uncapped after 1 hour to release built up gas. Tissues were left to digest for 2 days at room temperature. After 2 days, the samples were diluted down to 2.4% acid in MQ water and prepared for ICP-OES as mentioned above.
- XPS analysis of the sectioned tissue was conducted on a Thermo Fisher ESCALab 250Xi using Al K-alpha X-ray source (1486.6 eV) (Thermo Fisher Scientific, Waltham Mass.).
- the monochromated X-ray beam spot size was 300 ⁇ m in diameter and the power was 100 watts.
- a pass energy of 100 eV and step size of 1 eV were used for the survey scan.
- 50 eV of pass energy and a 0.1 eV step size were used.
- the dwell time was 50 ms.
- the XPS spectra were calibrated with adventitious carbon peak at 284.8 eV. All XPS data were processed with Avantage software.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.
Description
- The present application is a continuation of U.S. patent application Ser. No. 16/468,224, filed on Jun. 10, 2019, now U.S. Pat. No. 11,559,609, which is a § 371 U.S. National Entry Application based on PCT/US2017/065352, filed Dec. 8, 2017, which claims priority to U.S. Provisional Patent Application Ser. No. 62/432,266, filed Dec. 9, 2016, and to U.S. Provisional Patent Application Ser. No. 62/571,495, filed Oct. 12, 2017, each of which are incorporated by reference in their entireties.
- The text of the computer readable sequence listing filed herewith, titled “35106-304_SEQUENCE_LISTING”, created Jan. 24, 2023, having a file size of 5,335 bytes, is hereby incorporated by reference in its entirety.
- Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.
- Significant focus in the field of bone tissue engineering has been placed on developing materials for repair of bone defects. Much less work has been directed toward bone diseases. As such, material strength has been the main focus rather than the material's ability to induce bone formation. These materials are often hard, filler pastes that are biologically inert (e.g., methyl methacrylate) or brittle (e.g., calcium phosphate). Additionally, the challenges of inflammation and osteoporotic bone have been largely unexplored. An unmet need lies in the development of materials that can be used with a minimally invasive procedure to conform to unique fracture sites, can interact with the complex cellular environment to accelerate healing in all bone types, induce stem cells to become bone cells, and allow for localized drug delivery if necessary.
- Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.
- In some embodiments, provided herein are compositions comprising a PPCN-based hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers and at least one bioactive agent incorporated therein and/or appended thereto. In some embodiments, the bioactive agent is an additional monomer incorporated into the PPCN-based hydrogel backbone. In some embodiments, the bioactive agent is β-glycerophosphate. In some embodiments, the bioactive agent is a pendant group appended to a PPCN hydrogel. In some embodiments, the pendant group is a small molecule. In some embodiments, the pendant group is a peptide. In some embodiments, the bioactive agent is a cyclic Arg-Gly-Asp (cRGD) peptide. In some embodiments, the bioactive agent is an ionic crosslinking agent. In some embodiments, the bioactive agent is Ca2+, Ba2+, or Sr2+.
- In some embodiments, provided herein are compositions comprising a PPCN-based phosphate-displaying hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, poly-(N-isopropylacrylamide), and β-glycerophosphate monomers. In some embodiments, the PPCN-based phosphate-displaying hydrogel comprises the structure:
- wherein x and y are independently 2-20. In some embodiments, the composition is prepared by (a) polycondensation of citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and β-glycerophosphate monomers; followed by (b) free radical polymerization with poly-(N-isopropylacrylamide). In some embodiments, the composition is prepared by the reactions depicted in Scheme 1.
- In some embodiments, provided herein are compositions comprising a PPCN-based peptide-displaying hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers, and a peptide covalently conjugated to carboxy groups of the citric acid monomers. In some embodiments, the peptide is covalently conjugated via carbodiimide chemistry to carboxy groups of the citric acid monomers. In some embodiments, the peptide is cyclic Arg-Gly-Asp (cRGD). In some embodiments, the cRGD is covalently conjugated to carboxy groups of PPCN. In some embodiments, the composition is prepared by reactions depicted in
Scheme 2. - In some embodiments, provided herein are compositions comprising a PPCN-based hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers, and metal ion crosslinks. In some embodiments, compositions comprise metal-ion-crosslinked PPCN. In some embodiments, compositions are prepared by incubating the PPCN in the presence of a salt of the metal ion. In some embodiments, the metal ion is Ca2+, Ba2+, or Sr2+.
- In some embodiments, provided herein are methods of facilitating bone repair comprising administering a composition described herein (e.g., a PPCN-based hydrogel) to fractured or diseased bone site, and allowing the composition to gel.
- In some embodiments, provided herein is the use of a composition described herein (e.g., a PPCN-based hydrogel) to facilitate bone repair.
- The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.
-
FIG. 1 . (a) MALDI spectrum of PPCN-cRGD major peaks include expected ionized cyclic-RGDfC at 581.7 m/z and full monomer at 1156 m/z. (b) ICP-OES of 50 mM and 100 mM Sr2+ release from PPCN-Sr gels reveals majority of strontium is released in 1 week. FT-IR of PPCN-phos shows growth of peaks associated with reagent β-glycerophosphate, namely the broadening of the OH stretch at 3400 nm−1 and growth of a new peak around 1238 nm−1 attributed to phosphonate. Elemental analysis corroborates this data with a small reduction in carbon due to the displacement of carbon-rich PEG chains by β-glycerophosphate. -
FIG. 2 . Rheological characterization of PPCN (a) as compared to PPCN-cRGD (b), PPCN-Sr (c) and PPCN-phos (d) confirms that all three osteoinductive variants maintain thermoresponsive behavior and exhibit a lower LCST transition than PPCN. -
FIG. 3 . LIVE/DEAD imaging of hMSCs and MC3T3s seeded in 3D gels and cultured in regular DMEM. Cells were seeded in either alginate, PPCN, PPCN-cRGD, PPCN-Sr, or PPCN-phos gels. Cells grown in PPCN-cRGD gels show spreading morphology confirming the functionality of RGD is preserved post-conjugation. Viability in all gels is above 75%. Images were taken atday 10 and representative images shown from n=3 wells. -
FIG. 4 .Day day 10. However, significant increase in ALP is detected for MC3T3s grown in PPCN-Sr and PPCN-phos gels. *P-value<0.05 and **P-value<0.01. -
FIG. 5 .Day 21 characterization of hMSCs via staining for calcium deposition by Alizarin Red S, immunohistochemistry for osteopontin (OPN), and osteocalcin (OCN). Corresponding quantification is shown on the right. Mineralization is seen in all three functionalizations. From the data, osteopontin expression is highest in PPCN-Sr and osteocalcin expression is highest in PPCN-phos. -
FIG. 6 . MicroCT analysis of intramuscular femoral injection of PPCN and PPCN-Sr is shown fromday 0 today 42. The top right panel orients the microCT images onto the mouse femur. The bottom right panel shows the quantification of the microCT images, n=3. Mineralization is observed in the PPCN-Sr group beginning atday 10 and increasing consistently through the 6 week period. No mineralization is observed in the non-functionalized PPCN control. Mineralized regions were quantified with Osirix by threshold intensity and reconstructed to show the 3D inlay. -
FIG. 7 . PPCN-Sr demonstrates significant osteocalcin expression and cell infiltration (b) as compared to PPCN control (a). Alizarin Red S staining for mineralization also demonstrates robust mineralization in PPCN-Sr (d) as detected by red calcium deposits and compared to non-functionalized PPCN (c). Full tissue section is shown for PPCN and PPCN-Sr in (e) and (f), respectively. -
FIG. 8 .Day 42 ICP analysis of 8 mouse organs shows that strontium is not present in any of the main organs upon digestion (a). Additionally, XPS analysis of sectioned muscle tissue show that strontium is cleared and no longer present at the site of injection (b). XPS analysis shows calcium, phosphate and oxygen content consistent with mineralization in the PPCN-Sr group, but no local strontium remaining atweek 6. - Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments described herein, some preferred methods, compositions, devices, and materials are described herein. However, before the present materials and methods are described, it is to be understood that this invention is not limited to the particular molecules, compositions, methodologies or protocols herein described, as these may vary in accordance with routine experimentation and optimization. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope of the embodiments described herein.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. However, in case of conflict, the present specification, including definitions, will control. Accordingly, in the context of the embodiments described herein, the following definitions apply.
- As used herein and in the appended claims, the singular forms “a”, “an” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a polymer” is a reference to one or more polymers and equivalents thereof known to those skilled in the art, and so forth.
- As used herein, the term “and/or” includes any and all combinations of listed items, including any of the listed items individually. For example, “A, B, and/or C” encompasses A, B, C, AB, AC, BC, and ABC, each of which is to be considered separately described by the statement “A, B, and/or C.” As used herein, the term “comprise” and linguistic variations thereof denote the presence of recited feature(s), element(s), method step(s), etc. without the exclusion of the presence of additional feature(s), element(s), method step(s), etc. Conversely, the term “consisting of” and linguistic variations thereof, denotes the presence of recited feature(s), element(s), method step(s), etc. and excludes any unrecited feature(s), element(s), method step(s), etc., except for ordinarily-associated impurities. The phrase “consisting essentially of” denotes the recited feature(s), element(s), method step(s), etc. and any additional feature(s), element(s), method step(s), etc. that do not materially affect the basic nature of the composition, system, or method. Many embodiments herein are described using open “comprising” language. Such embodiments encompass multiple closed “consisting of” and/or “consisting essentially of” embodiments, which may alternatively be claimed or described using such language.
- As used herein, the term “substantially all,” “substantially complete” and similar terms refer to greater than 99%; and the terms “substantially none,” “substantially free of,” and similar terms refer to less than 1%.
- The term “about” allows for a degree of variability in a value or range. As used herein, the term “about: refers to values within 10% of the recited value or range (e.g., about 50 is the equivalent of 45-55).
- As used herein, the term “polymer” refers to a chain of repeating structural units or “monomers”, typically of large molecular mass. Examples of polymers include homopolymers (single type of monomer subunits), copolymers (two types of monomer subunits), and heteropolymers (e.g., three or more types of monomer subunits). As used herein, the term “oligomer” refers to a polymer of only a few monomer units (e.g., 2, 3, 4, 5, or more) up to about 50 monomer units, for example a dimer, trimer, tetramer, pentamer, hexamer . . . decamer, etc.
- As used herein, the term “linear polymer” refers to a polymer in which the molecules form long chains without branches or crosslinked structures.
- As used herein, the term “branched polymer” refers to a polymer comprising a polymer backbone with one or more additional monomers, or chains or monomers, extending from polymer backbone. The degree of interconnectedness of the “branches” is insufficient to render the polymer insoluble.
- As used herein, the term “pre-polymer” refers to linear or branched polymers (e.g., not significantly crosslinked) that have the capacity to be crosslinked under appropriate conditions (e.g., to “cure” and/or form a thermoset or hydrogel), but have not been subjected to the appropriate conditions.
- As used herein, the term “crosslinked polymer” refers to a polymer with a significant degree of interconnectedness between multiple polymer strands, the result of which is an insoluble polymer network. For example, multiple polymer stands may be crosslinked to each other at points within their structures, not limited to the ends of the polymer chains.
- As used herein, the term “biocompatible” refers to materials, compounds, or compositions means that do not cause or elicit significant adverse effects when administered to a subject. Examples of possible adverse effects that limit biocompatibility include, but are not limited to, excessive inflammation, excessive or adverse immune response, and toxicity.
- As used herein, the term “hydrogel” refers to a three-dimensional (3D) crosslinked network of hydrophilic polymers that swells, rather than being dissolved, in water.
- As used herein, the term “thermoresponsive” refers to material that exhibit altered physical characteristics at different temperature ranges. Particularly relevant herein are “phase-transitioning thermoresponsive” materials. Phase-transitioning thermoresponsive” materials are soluble or in a liquid state at a first temperature range (e.g., below 26° C.) and insoluble or in a solid state at a second temperature range (e.g., 30-45° C.).
- Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material for ions or therapeutics, and gel at body temperature to allow for controlled release. In some embodiments, materials are antioxidant and can promote bone formation based on material properties, without osteogenic supplementation. In some embodiments, materials comprise, for example, bone-promoting agents, such as phosphate, cRGD, and/or strontium.
- In some embodiments, provided herein are thermoresponsive hydrogels comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers. In some embodiments, thermoresponsive hydrogels are PPCN-based hydrogels. In some embodiments, a PPCN-based hydrogel comprises citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers and one or more additional monomer groups (e.g., β-glycerophosphate). In some embodiments, a PPCN-based hydrogel comprises citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers and is conjugated to one or more bioactive agents (e.g., metal ions (e.g., Sr2+), peptides (e.g., cRGD), etc.).
- In some embodiments, negatively-charged carboxyl groups on the PPCN-based hydrogels (e.g., displayed on the citric acid monomers) conjugate positively charged metal ions (e.g., Sr2+, Ca2+, Ba2+, etc.). In some embodiments, coordination of metal ions by separate carboxyl groups results in crosslinks in the PPCN-based polymer. In some embodiments, materials herein are not limited by the identity of the metal ion. In some embodiments, metal ions are introduced as salts to the PPCN-based materials.
- In some embodiments, carboxyl groups on the PPCN-based hydrogels (e.g., displayed on the citric acid monomers) are conjugated via appropriate linker chemistry to peptides or bioactive small molecules. In some embodiments, suitable chemistires for linking bioactive peptides and/or small molecules to the PPCN-based hydrogels include alkyne/azide, thiol/maleimide, thiol/haloacetyl (e.g., iodoacetyl, etc.), thiol/pyridyl disulfide (e.g. pyridyldithiol, etc.), sulphonyl azides/thio acids, etc.
- In some embodiments, a bioactive peptide that facilitate bone healing and/or repair is conjugated to a PPCN-based hydrogel. Suitable peptides include the P-15 peptide (Bhatnagar et al. Tissue Eng.1999; 5(1):53-65.; incorporated by reference in its entirety), an RGD containing peptide (Ruoslahti & Pierschbacher. Cell. 1986; 44(4):517-8.; incorporated by reference in its entirety), GFOGER (glycine-phenylalanine-hydroxyproline-glycine-glutamate-arginine) (SEQ ID NO: 1), collagen-binding motif (CBM), DGEA (Asp-Gly-Glu-Ala) (SEQ ID NO: 2), SVVYGLR (Ser-Val-Val-Tyr-Gly-Leu-Arg) (SEQ ID NO: 3), KRSR (lysine-arginine-serine-arginine) (SEQ ID NO: 4), FHRRIKA (Phe-His-Arg-Arg-Ile-Lys-Ala) (SEQ ID NO: 5), Fibronectin (FN)-derived peptides, and other ECM-derived peptides (Pountos et al. BMC Med. 2016; 14: 103.; incorporated by reference in its entirety).
- In some embodiments, PPCN or a PPCN-based polymer or hydrogel comprises comprise at least 0.1% citric acid monomers (e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%). In some embodiments, polymers herein comprise less than 99% citric acid monomers (e.g., <99%, <98%, <95%, <90%, <80%, <70%, <60%, <50%, <40%, <30%, <20%,<10%, <5%,<4%, <3%, <2%, <1%, <0.5%,). In some embodiments, polymers comprise about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% citric acid monomers.
- In some embodiments, PPCN or a PPCN-based polymer or hydrogel comprises comprise at least 0.1% polyethylene glycol monomers (e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%). In some embodiments, polymers herein comprise less than 99% polyethylene glycol monomers (e.g., <99%, <98%, <95%, <90%, <80%, <70%, <60%, <50%, <40%, <30%, <20%,<10%, <5%,<4%, <3%, <2%, <1%, <0.5%,). In some embodiments, polymers comprise about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% polyethylene glycol monomers.
- In some embodiments, PPCN or a PPCN-based polymer or hydrogel comprises at least 0.1% glycerol 1,3- diglycerolate diacrylate monomers (e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%). In some embodiments, polymers herein comprise less than 99% glycerol 1,3- diglycerolate diacrylate monomers (e.g., <99%, <98%, <95%, <90%, <80%, <70%, <60%, <50%, <40%, <30%, <20%,<10%, <5%,<4%, <3%, <2%, <1%, <0.5%). In some embodiments, polymers comprise about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% glycerol 1,3-diglycerolate diacrylate monomers.
- In some embodiments, PPCN or a PPCN-based polymer or hydrogel comprises at least 0.1% N-isopropylacrylamide monomers (e.g., >0.1%, >0.2%, >0.5%, >1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%). In some embodiments, polymers herein comprise less than 99% N-isopropylacrylamide monomers (e.g., <99%, <98%, <95%, <90%, <80%, <70%, <60%, <50%, <40%, <30%, <20%,<10%, <5%,<4%, <3%, <2%, <1%, <0.5%). In some embodiments, polymers comprise about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0.5% N-isopropylacrylamide monomers.
- In some embodiments, materials described herein comprise composites of the PPCN-based thermoresponsive hydrogel materials described herein and one or more additional components. In some embodiments, additional components comprise 1-99 wt % of the composite material (e.g., 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or ranges therebetween). In some embodiments, a composite material comprises at least 1% (e.g., >>1%, >2%, >3%, >4%, >5%, >10%, >20%, >30%, >40%, >50%, >60%, >70%, >80%, >90%, >95%, >98%, >99%) PPCN-based hydrogel. In some embodiments, a thermoresponsive composite material comprises less than 99% (e.g., <99%, <98%, <95%, <90%, <80%, <70%, <60%, <50%, <40%, <30%, <20%, <10%, <5%,<4%, <3%, <2%, <1%) PPCN-based hydrogel. In some embodiments, a composite material comprises a PPCN-based hydrogel in an amount of about 99%, about 98%, about 95%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, or ranges therebetween. The aforementioned percentages may be wt % or molar %.
- In some embodiments, composites of thermoresponsive PPCN-based hydrogel materials and a bioceramic component are provided. Suitable bioceramics include hydroxyapatite (HA; Ca10(PO4)6(OH)2), tricalcium phosphate beta (β TCP; Ca3(PO4)2), and mixtures of HAP and β TCP.
- In some embodiments, composite materials comprise a PPCN-based hydrogel and one or more additional polymeric components. Suitable biodegradeable polymers include, but are not limited to: collagen, elastin, hyaluronic acid and derivatives, sodium alginate and derivatives, chitosan and derivatives gelatin, starch, cellulose polymers (for example methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), casein, dextran and derivatives, polysaccharides, poly(caprolactone), fibrinogen, poly(hydroxyl acids), poly(L-lactide) poly(D,L lactide), poly(D,L-lactide-co-glycolide), poly(L-lactide-co-glycolide), copolymers of lactic acid and glycolic acid, copolymers of ε-caprolactone and lactide, copolymers of glycolide and ε-caprolactone, copolymers of lactide and 1,4-dioxane-2-one, polymers and copolymers that include one or more of the residue units of the monomers D-lactide, L-lactide, D,L-lactide, glycolide, ε-caprolactone, trimethylene carbonate, 1,4-dioxane-2-one or 1,5-dioxepan-2-one, poly(glycolide), poly(hydroxybutyrate), poly(alkylcarbonate) and poly(orthoesters), polyesters, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene terephthalate), poly(malic acid), poly(tartronic acid), polyanhydrides, polyphosphazenes, poly(amino acids), and copolymers of the above polymers as well as blends and combinations of the above polymers. (See generally, Illum, L., Davids, S. S. (eds.) “Polymers in Controlled Drug Delivery” Wright, Bristol, 1987; Arshady, J. Controlled Release 17:1-22, 1991; Pitt, Int. J. Phar. 59:173-196, 1990; Holland et al., J. Controlled Release 4:155-0180, 1986; herein incorporated by reference in their entireties). Suitable non-biogregradable polymers include silicone rubber, polyethylene, acrylic resins, polyurethane, polypropylene, and polymethylmethacrylate.
- As described throughout, provided herein are PPCN-based materials comprising curable (e.g., thermoresponsive) hydrogels and/or and composites thereof. These materials find use in a variety of applications. For example, any application in which it is desired that a material be applied in a liquid and/or soluble form, and then is (rapidly) rendered solid and/or insoluble when exposed to desired conditions (e.g., physiological temperature). Materials described herein find use, for example, in medical and dental bone repair applications, such as, repair of craniofacial injuries, stabilizing complex fractures, promoting bone growth, bone regeneration, as a bone-void filler, adhering implants, etc. In some embodiments, materials find use in non-medical/dental applications. In some embodiments, the PPCN-based materials described herein are liquid at sub-physiologic temperatures (e.g., 36° C., 35° C., 34° C., 33° C., 32° C., 31° C., 30° C., 29° C., 28° C., 27° C., 26° C., 25° C., 24° C., 23° C., 22° C., 21° C., 20° C., or lower or ranges therebetween). In some embodiments, the PPCN-based materials described herein gel at or near physiologic temperatures (e.g., 30° C., 31° C., 32° C., 33° C., 34° C., 35° C., 36° C., 37° C., 38° C., 39° C., 40° C., or ranges therebetween).
- In some embodiments in which the materials herein are used for the repair, stabilization, regeneration, growth, etc. of bone or bone fractures/injuries, the materials further comprise additional components/agents to facilitate incorporation into bone, bone growth, bone regeneration, etc. In some embodiments, additional components/agents are incorporated into the materials and are subsequently encapsulated within the material upon curing. In such embodiments, additional components/agents are non-covalently associated with the PPCN-based hydrogels and other components of the materials. In other embodiments, additional components/agents are covalently-linked PPCN-based hydrogel.
- In some embodiments, the materials described herein find use in the delivery of growth factors or other bioactive agents for the repair of bone defects and/or regeneration of bone. Suitable agents for use in embodiments herein include bone morphogenic proteins (e.g., BMP-1, BMP-2, BMP-4, BMP-6, and BMP-7); members of the transforming growth factor beta (TGF-β) superfamily including, but not limited to, TGF-β1, TGF-β2, and TGF-β3; growth differentiation factors (GDF1, GDF2, GDF3, GDFS, GDF6, GDF7, myostatin/GDF8, GDF9, GDF10, GDF11, and GDF15); vascular endothelial growth factor (VEGF); fibroblast growth factor (FGF); etc. These agent, or others, may be covalently linked to materials described herein or components thereof, non-covalently associated with moieties displayed on materials described herein or components thereof, embedded within materials described herein, etc.
- In some embodiments, the PPCN-based hydrogels herein find use as a carrier for therapeutics (e.g., osteoporotic drugs), cells (e.g., stem cells), growth factors, etc. In some embodiments, the PPCN-based hydrogels herein provide controlled, localized delivery of bioactive agents encapsulated therein.
- In some embodiments, provided herein are methods comprising administering a composition comprising a PPCN-based hydrogel described herein to a bone defect or fracture. In some embodiments, provided herein is the use of a PPCN-based hydrogel described herein to repair a bone defect or fracture.
- In some embodiments, the PPCN-based hydrogels described herein are injected into a fracture site (e.g., during orthopedic surgery) to facilitate and/or accelerate healing.
- For gel studies, human mesenchymal stem cells (hMSCs, ATCC) were cultured in Dulbecco's Modified Eagle medium (DMEM) and supplemented with 10% FBS and 5
ml 10× penicillin-streptomycin with no further osteogenic supplementation. hMSCs used in these studies were atpassage 6 or below. Murine pre-osteoblast MC3T3-E1 cells (ATCC) were cultured in DMEM:F12. Both cell lines were cultured at 37° C. and 5% carbon dioxide (CO2). - PPCN (poly (polyethylene glycol citrate-co-N-isopropylacrylamide) was prepared by polycondensation and subsequent radical polymerization.
- To prepare PPCN-phos, the original PPCN synthesis was adjusted to add 0.1 molar ratio of β-glycerophosphate in the first polycondensation step (Scheme 1). The subsequent reaction steps were unchanged.
-
- Scheme 1. Synthetic scheme of PPCN-phos synthesis. β-glycerophosphate was added during step 1 (polycondensation) of PPCN synthesis in 0.1 or 0.2 molar ratios. The proposed locations of phosphate attachment are shown—specifically via reaction between the reactive hydroxyls of β-glycerophosphate and the available carboxyl groups of citric acid. PPCN-phos of 0.1 molar ratio was used in subsequent cell studies because higher molar ratios exhibited overcrosslinking.
- To prepare PPCN-cRGD gels, PPCN was formed as reported. Then, cyclic RGDfC peptide (ABI Scientific) was covalently conjugated via maleimide chemistry to the available carboxy groups of citric acid within the PPCN polymer chain (Scheme 2). The intended density of cyclic RGD peptide was 10%.
-
-
Scheme 2. Synthetic scheme of PPCN-Sr and PPCN-cRGD syntheses. PPCN was prepared by polycondensation and subsequent free radical polymerization as previously reported. Then, PPCN-cRGD gels were prepared by covalently conjugating cyclic RGDfC peptide via maleimide chemistry to the available carboxylic acid groups of citric acid within the PPCN polymer chain. To prepare PPCN-Sr gels, PPCN was dissolved in PBS (1×) at 100 mg/ml. 100 mM of SrCl2 6H2O (Sigma) was mixed into PPCN/PBS solutions and left to crosslink overnight at 4° C. prior to use.
-
- To prepare PPCN-Sr gels, PPCN was dissolved in PBS (1×) at 100 mg/ml. 100 mM of SrCl2 6H2O (Sigma) was mixed into PPCN/PBS solutions and left to crosslink overnight at 4° C. (Scheme 2).
- Characterization for gels is shown in
FIG. 1 . PPCN-cRGD conjugation was confirmed by matrix assisted laser desorption ionization (MALDI) (FIG. 1 a ). The samples were prepared with an alpha-cyano-4-hydroxycinnamic acid matrix. PPCN-Sr was characterized by a strontium release study via inductively coupled plasma optical emission spectroscopy (Thermo iCAP 7600 ICP-OES). Gels were immersed in simulated body fluid and solution was removed over a 14 day time course and assayed for Sr2+ concentration (FIG. 1 b ). PPCN-phos was characterized by FT-IR (Bruker Tensor 37) and XPS (FIG. 1 c ). Further rheological characterization was carried out on a TA instruments DHR rheometer with a 20mm 2° cone peltier plate geometry and solvent trap cover to minimize sample evaporation. Gels were studied in a temperature ramp experiment from 15° C. to 45° C. with a heating rate of 5° C./min. The viscoelastic moduli were monitored at an applied angular frequency of 10 rad/s and strain amplitude of 5%. A gap height of 52 μm was used for all samples. The initial change in viscoelastic properties was characterized by an increase of storage modulus (G′) over loss modulus (G″). - Cells were encapsulated in various thermoresponsive PPCN solutions of 100 mg/mL PPCN in PBS (1×). Cells were added to solution via uniform mixing at a concentration of 1×105 cells/mL liquid PPCN. The cell-PPCN mixture was incubated at 37° C. for 5 min to allow gels to form. Once the gel was formed, warm media was added on top and changed every 2 days. Prior to seeding, the plate was coated with Sigma-cote to prevent cell attachment to the plate, ensuring that all cells that persist through media changes persist within the 3D gel environment. During handling, the plates were kept on a plate-warmer to ensure the gel would not be dissolved or diluted as a result of temperature fluctuations. At each time-point, the media was removed and the gel was collected and frozen in the case of ALP and DNA analysis or assayed directly in the case of LIVE/DEAD, alizarin red staining, and immunohistochemistry.
- For early detection of osteodifferentiation (
FIG. 4 ), alkaline phosphatase (ALP) was measured. The gels were collected atday 3 andday 10 and extracellular alkaline phosphatase (ALP) activity was detected by a fluorometric kit (Biovision). A non-fluorescent substrate, 4-Methylumelliferyl phosphate disodium salt (MUP), was added and cleaved by ALP, which results in a fluorescent signal (Ex/Em=360/440 nm). The fluorescence was read on a micro-plate reader. The enzymatic activity was calculated based on serially diluted gel standards and normalized to total DNA content with a concurrent Quant-iT PicoGreen assay (Thermo Fisher). - For late detection of osteodifferentiation (
FIG. 5 ), Alizarin Red S staining and immunohistochemistry for osteocalcin (OCN) and osteopontin (OPN) was performed. For Alizarin Red S, the cells were fixed inside the warmed gels and stain was allowed to permeate gels while excess stain was subsequently rinsed out with several washes of DI water. Mineralization was visualized with light microscopy. For immunohistochemistry, the cells were fixed inside the warmed gels and primary antibodies for OPN or OCN were added and counterstained with DAPI. - To assess mineralization, mice were anesthetized with isoflurane and placed on the heated microCT bed. Images were acquired with a preclinical microPET/CT imaging system, nanoScan scanner (Mediso-USA, Boston, Mass.). Data were acquired with “medium” magnification, 33 μm focal spot, 1×1 binning, with 720 projection views over a full circle, with a 300 ms exposure time. Images were acquired using 35 kVp. The projection data was reconstructed with a voxel size of 68 μm using filtered back-projection software from Mediso. The reconstructed data were visualized and segmented in Osirix Lite for Mac. Using the coronal plane, images were quantified by creating regions of interest (ROI) with 2D region-growing using a lower threshold of 600 and an upper threshold of 10,000 Hounsfield units (HU). The regions of interests (ROIs) were used for quantification of mineralization by calculating the mean HU for each ROI (bone is 700 to 3,000 HU).
- Animals were euthanized by carbon dioxide inhalation. Tissues were collected and fixed by 4% paraformaldehyde in PBS overnight at 4° C. Samples were washed by PBS with several changes to remove paraformaldehyde residue. The samples were dehydrated by series ethanol, cleared by xylene, and embedded in paraffin. Sections of 5 micron thickness were cut and mounted on slides. Sections were treated by xylene to remove paraffin, hydrated by alternating ethanol and water. Slides were immersed into antigen retrieval buffer (10 mM Sodium citrate, 0.05
% Tween 20, pH 6.0) and heated at 100° C. for 15 min. After washed by PBS, the samples were blocked by 5 mg/mL BSA, 5% normal goat serum in PBS for 30 min. Samples were incubated with primary antibody diluted in blocking buffer at 4° C. overnight. Slides were washed byPBS 3×5 min, then incubated with secondary antibody diluted by blocking buffer at room temperature for 30 min. Slides were washed byPBS 6×5 min, then mounted with anti-fade medium and sealed by nail polish. Images were taken by Nikon TE-2000U microscopy or Cytation5 image reader. - Strontium distribution was assayed in several main organs namely the heart, brain, spleen, testes, muscle, lung, kidney, and liver. After euthanization, each organ was collected and stored in −80° C. until analysis. Tissue digestion was carried out by adding 70% nitric acid and 37% hydrogen peroxide to each sample. Samples were uncapped after 1 hour to release built up gas. Tissues were left to digest for 2 days at room temperature. After 2 days, the samples were diluted down to 2.4% acid in MQ water and prepared for ICP-OES as mentioned above.
- XPS analysis of the sectioned tissue was conducted on a Thermo Fisher ESCALab 250Xi using Al K-alpha X-ray source (1486.6 eV) (Thermo Fisher Scientific, Waltham Mass.). The monochromated X-ray beam spot size was 300 μm in diameter and the power was 100 watts. A pass energy of 100 eV and step size of 1 eV were used for the survey scan. For the high resolution scan, 50 eV of pass energy and a 0.1 eV step size were used. The dwell time was 50 ms. The XPS spectra were calibrated with adventitious carbon peak at 284.8 eV. All XPS data were processed with Avantage software.
Claims (20)
1. A composition comprising a PPCN-based hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers and at least one bioactive agent incorporated therein and/or appended thereto.
2. The composition of claim 1 , wherein the bioactive agent is an additional monomer incorporated into the PPCN-based hydrogel backbone.
3. The composition of claim 2 , wherein the bioactive agent is β-glycerophosphate.
4. The composition of claim 1 , wherein the bioactive agent is a pendant group appended to a PPCN hydrogel.
5. The composition of claim 4 , wherein the pendant group is a small molecule.
6. The composition of claim 4 , wherein the pendant group is a peptide.
7. The composition of claim 6 , wherein the bioactive agent is a cyclic Arg-Gly-Asp (cRGD) peptide.
8. The composition of claim 1 , wherein the bioactive agent is an ionic crosslinking agent.
9. The composition of claim 8 , wherein the bioactive agent is Ca2+, Ba2+, or Sr2+.
10-13. (canceled)
14. A composition comprising a PPCN-based peptide-displaying hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers, and a peptide covalently conjugated to carboxy groups of the citric acid monomers.
15. The composition of claim 14 , wherein the peptide is covalently conjugated via carbodiimide chemistry to carboxy groups of the citric acid monomers.
16. The composition of claim 14 , wherein the peptide is cyclic Arg-Gly-Asp (cRGD).
17. The composition of claim 16 , wherein the cRGD is covalently conjugated to carboxy groups of PPCN.
18. A composition comprising a PPCN-based hydrogel comprising citric acid, poly(ethylene glycol), glycerol 1,3-diglycerolate diacrylate, and poly-(N-isopropylacrylamide) monomers, and metal ion crosslinks.
19. The composition of claim 18 , comprising metal-ion-crosslinked PPCN.
20. The composition of claim 19 , prepared by incubating the PPCN in the presence of a salt of the metal ion.
21. The composition of claim 19 , wherein the metal ion is Ca2+, Ba2+, or Sr2+.
22. A method of facilitating bone repair comprising administering a composition of claim 1 to fractured or diseased bone site, and allowing the composition to gel.
23. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/158,746 US20230293775A1 (en) | 2016-12-09 | 2023-01-24 | Bone-promoting thermoresponsive macromolecules |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662432266P | 2016-12-09 | 2016-12-09 | |
US201762571495P | 2017-10-12 | 2017-10-12 | |
PCT/US2017/065352 WO2018107049A1 (en) | 2016-12-09 | 2017-12-08 | Bone-promoting thermoresponsive macromolecules |
US201916468224A | 2019-06-10 | 2019-06-10 | |
US18/158,746 US20230293775A1 (en) | 2016-12-09 | 2023-01-24 | Bone-promoting thermoresponsive macromolecules |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/065352 Continuation WO2018107049A1 (en) | 2016-12-09 | 2017-12-08 | Bone-promoting thermoresponsive macromolecules |
US16/468,224 Continuation US11559609B2 (en) | 2016-12-09 | 2017-12-08 | Bone-promoting thermoresponsive macromolecules |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230293775A1 true US20230293775A1 (en) | 2023-09-21 |
Family
ID=62492224
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/468,224 Active 2038-09-22 US11559609B2 (en) | 2016-12-09 | 2017-12-08 | Bone-promoting thermoresponsive macromolecules |
US18/158,746 Pending US20230293775A1 (en) | 2016-12-09 | 2023-01-24 | Bone-promoting thermoresponsive macromolecules |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/468,224 Active 2038-09-22 US11559609B2 (en) | 2016-12-09 | 2017-12-08 | Bone-promoting thermoresponsive macromolecules |
Country Status (7)
Country | Link |
---|---|
US (2) | US11559609B2 (en) |
EP (1) | EP3551177A4 (en) |
JP (1) | JP2020501661A (en) |
CN (1) | CN110198710A (en) |
AU (2) | AU2017370749A1 (en) |
CA (1) | CA3046522A1 (en) |
WO (1) | WO2018107049A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3107985A1 (en) | 2018-07-27 | 2020-01-30 | The Penn State Research Foundation | Compositions and methods for promoting bone regeneration |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU746591B2 (en) | 1998-10-19 | 2002-05-02 | Synthes Gmbh | Hardenable ceramic hydraulic cement |
US8663225B2 (en) | 2004-11-12 | 2014-03-04 | Medtronic, Inc. | Hydrogel bone void filler |
MX2009011268A (en) | 2007-04-23 | 2009-11-02 | Baxter Int | Fibrin compositions containing strontium compounds. |
GB0717516D0 (en) * | 2007-09-07 | 2007-10-17 | Imp Innovations Ltd | Bioactive nanocomposite material |
EP2672998B1 (en) | 2011-01-31 | 2018-06-27 | Northwestern University | Injectable thermoresponsive polyelectrolytes |
WO2016100847A2 (en) * | 2014-12-20 | 2016-06-23 | Northwestern University | Polymer metal-organic framework composites |
EP3294312B1 (en) * | 2015-05-12 | 2020-07-08 | Northwestern University | Materials for tissue regeneration |
US20160346382A1 (en) * | 2015-05-27 | 2016-12-01 | Northwestern University | Carbohydrate-modified particles and particulate formulations for modulating an immune response |
-
2017
- 2017-12-08 AU AU2017370749A patent/AU2017370749A1/en not_active Abandoned
- 2017-12-08 CA CA3046522A patent/CA3046522A1/en active Pending
- 2017-12-08 JP JP2019531139A patent/JP2020501661A/en active Pending
- 2017-12-08 US US16/468,224 patent/US11559609B2/en active Active
- 2017-12-08 EP EP17877808.0A patent/EP3551177A4/en active Pending
- 2017-12-08 CN CN201780082490.6A patent/CN110198710A/en active Pending
- 2017-12-08 WO PCT/US2017/065352 patent/WO2018107049A1/en unknown
-
2023
- 2023-01-24 US US18/158,746 patent/US20230293775A1/en active Pending
-
2024
- 2024-01-18 AU AU2024200341A patent/AU2024200341A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3551177A1 (en) | 2019-10-16 |
US20190336648A1 (en) | 2019-11-07 |
JP2020501661A (en) | 2020-01-23 |
WO2018107049A1 (en) | 2018-06-14 |
CN110198710A (en) | 2019-09-03 |
CA3046522A1 (en) | 2018-06-14 |
EP3551177A4 (en) | 2020-07-08 |
US11559609B2 (en) | 2023-01-24 |
AU2024200341A1 (en) | 2024-04-04 |
AU2017370749A1 (en) | 2019-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Almeida et al. | Fibrin hydrogels functionalized with cartilage extracellular matrix and incorporating freshly isolated stromal cells as an injectable for cartilage regeneration | |
Gronowicz et al. | Calvarial bone regeneration is enhanced by sequential delivery of FGF-2 and BMP-2 from layer-by-layer coatings with a biomimetic calcium phosphate barrier layer | |
CA2922924C (en) | Bioelastomers and applications thereof | |
Li et al. | Matrix metalloproteinase (MMP)-degradable tissue engineered periosteum coordinates allograft healing via early stage recruitment and support of host neurovasculature | |
AU2024200341A1 (en) | Bone-promoting thermoresponsive macromolecules | |
US8575311B2 (en) | Collagen peptide conjugates and uses therefor | |
Bain et al. | Enhancement of the regenerative potential of anorganic bovine bone graft utilizing a polyglutamate-modified BMP2 peptide with improved binding to calcium-containing materials | |
JP6286447B2 (en) | Compositions containing citrate and applications thereof | |
Olvera et al. | Spatial presentation of tissue-specific extracellular matrix components along electrospun scaffolds for tissue engineering the bone–ligament interface | |
Liu et al. | Injectable catalyst-free “click” organic-inorganic nanohybrid (click-ON) cement for minimally invasive in vivo bone repair | |
CN108392680A (en) | Biomaterial is filled by a kind of shaping degradable sclerous tissues | |
RU2556806C2 (en) | Peptide, capable of regenerating bone tissue and binding with apatite | |
Kim et al. | Osteochondral and bone tissue engineering scaffold prepared from Gallus var domesticus derived demineralized bone powder combined with gellan gum for medical application | |
Sun et al. | Three-dimensional bioprinted BMSCs-laden highly adhesive artificial periosteum containing gelatin-dopamine and graphene oxide nanosheets promoting bone defect repair | |
EP2588489A2 (en) | Biomimetic peptides for bone augmentation | |
Ye et al. | Injectable, hierarchically degraded bioactive scaffold for bone regeneration | |
Mohseni et al. | Dexamethasone loaded injectable, self-healing hydrogel microspheres based on UPy-functionalized Gelatin/ZnHAp physical network promotes bone regeneration | |
Bashur et al. | Composition of intraperitoneally implanted electrospun conduits modulates cellular elastic matrix generation | |
EP2547690B1 (en) | Affinity peptides toward bmp-2 | |
US20200095341A1 (en) | Functionalization of biopolymers with growth factor-binding peptides | |
US20210369812A1 (en) | Osteoinductive peptides, compositions, implants, and methods of use | |
Qiu et al. | Preparation of an injectable and photocurable carboxymethyl cellulose/hydroxyapatite composite and its application in cranial regeneration | |
Mahmoudi et al. | An Elastin‐Derived Composite Matrix for Enhanced Vascularized and Innervated Bone Tissue Reconstruction: From Material Development to Preclinical Evaluation | |
Iftekhar | Isolation of Fibrillar Elastin Gel (FEG) and its application in heart valve tissue engineering | |
Tansık | Bioactive Peptide Nanofibers for Bone Tissue Regeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: NORTHWESTERN UNIVERSITY, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AMEER, GUILLERMO A;MOROCHNIK, SIMONA;REEL/FRAME:065853/0966 Effective date: 20190620 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |